Platinum Moiety Research Articles

Reactions of Cisplatin with Thioredoxin-1 Regulate Intracellular Redox Homeostasis.

Cisplatin is a widely used anticancer drug. In addition to inducing DNA damage, increased levels of reactive oxygen species (ROS) play a significant role in cisplatin-induced cell death. Thioredoxin-1 (Trx1), a redox regulatory protein that can scavenge ROS, has been found to eliminate cisplatin-induced ROS, while elevated Trx1 levels are associated with cisplatin resistance. However, it is unknown whether the effect of Trx1 on the cellular response to cisplatin is due to its direct reaction and how this reaction influences the activity of Trx1. In this work, we performed detailed studies of the reaction between Trx1 and cisplatin. Trx1 is highly reactive to cisplatin, and the catalytic motif of Trx1 (CGPC) is the primary binding site of cisplatin. Trx1 can bind up to 6 platinum moieties, resulting in the structural alteration and oligomerization of Trx1 depending on the degree of platination. Platination of Trx1 inhibits its interaction with ASK1, a Trx1-binding protein that regulates cell apoptosis. Furthermore, the reaction with cisplatin suppresses drug-induced ROS generation, which could be associated with drug resistance. This study provides more insight into the mechanism of action of cisplatin.

A Platinum-Aluminum Bimetallic Salen Complex for Pro-senescence Cancer Therapy.

Cell senescence is defined as irreversible cell cycle arrest, which can be triggered by telomere shortening or by various types of genotoxic stress. Induction of senescence is emerging as a new strategy for the treatment of cancer, especially when sequentially combined with a second senolytic drug capable of killing the resulting senescent cells, however severely suffering from the undesired off-target side effects from the senolytic drugs. Here, we prepare a bimetalic platinum-aluminum salen complex (Alumiplatin) for cancer therapy-a combination of pro-senesence chemotherapy with in situ senotherapy to avoid the side effects. The aluminum salen moiety, as a G-quadruplex stabilizer, enhances the salen's ability to induce cancer cell senescence and this phenotype is in turn sensitive to the cytotoxic activity of the monofunctional platinum moiety. It exhibits an excellent capability for inducing senescence, a potent cytotoxic activity against cancer cells both in vitro and in vivo, and an improved safety profile compared to cisplatin. Therefore, Alumiplatin may be a good candidate to be further developed into safe and effective anticancer agents. This novel combination of cell senescence inducers with genotoxic drugs revolutionizes the therapy options of designing multi-targeting anticancer agents to improve the efficacy of anticancer therapies.

Platinum monolayer dispersed on MXenes for electrocatalyzed hydrogen evolution: a first-principles study.

Maximizing platinum's atomic utilization and understanding the anchoring mechanism between platinum moieties and their supports are crucial for the hydrogen evolution reaction (HER). Using density functional theory, we investigate the catalyst of a Pt monolayer on the two-dimensional Mo2TiC2 substrate (PtML/Mo2TiC2) for the reaction. This Pt monolayer shows a Pt(111)-like pattern, with its Pt-Pt bond elongated by about 0.1 Å compared to Pt(111); charge transfer from Mo2TiC2 to the Pt monolayer leads to significant charge accumulation on Pt. This substantial monolayer metal-support interaction optimizes hydrogen adsorption toward optimal HER activity under both constant charge and potential conditions, making PtML/Mo2TiC2 a promising HER catalyst. Detailed studies reveal that the dominant Volmer-Tafel mechanism in the HER occurs on the 1 monolayer hydrogen-covered PtML/Mo2TiC2 surface. The surface Pourbaix diagram identifies this as the stable surface termination under the electrochemical reaction conditions. These findings provide insights into designing stable, efficient, and low platinum-loaded HER catalysts.

Electrostatic vs. electronic interactions within oxidized multinuclear Pt(bipyridine)(dithiolene) complexes.

Bi- and trimetallic platinum(bipyridine)(dithiolene) complexes involving different organic linkers between the redox active platinum(dithiolene) moieties have been synthesized and studied by electrochemistry and spectroelectrochemistry. Cyclic voltammetry experiments carried out on these multinuclear complexes in dichloromethane using [NBu4][PF6] as the supporting salt show only one oxidation process involving the metallacycles. Nevertheless, spectro-electrochemical studies, carried out under the same conditions, show a different evolution of the spectra during oxidation depending on the position of the metallacycles on the phenyl ring. For instance, only the 1,3-disubtituted (Pt21,3-P) and 1,3,5-trisubstituted (Pt31,3,5-P) complexes show the growth of an absorption band in the NIR region upon oxidation while it was not observed for the other complexes. In contrast, electrochemical studies carried out using the poorly coordinating supporting electrolyte, [Na][B(C6H4(CF3)2)4], indicate sequential oxidation of the redox centers with ΔE values varying according to the nature of the bridge and the distance between metal centers. For all the investigated multinuclear complexes, spectro-electrochemical experiments performed in the presence of [Na][B(C6H4(CF3)2)4] show an absorption band in the NIR region consistent with appreciable electrostatic effects and charge delocalization in the mixed valent intermediates.

A novel benzothiazole-based mononuclear platinum(II) complex displaying potent antiproliferative activity in HepG-2 cells via mitochondrial-mediated apoptosis

A novel mononuclear platinum(II) complex, [Pt(L-H)Cl] (1, where L= N-(4-(benzo[d]thiazol-2-yl)phenyl)-2-((2-pyridylmethyl)(2-hydroxyethyl)-amino)acetamide), was obtained by covalently tethering a benzothiazole derivative 2-(4-aminophenyl)benzothiazole to the 2-pyridylmethyl-2-hydroxyethylamine chelating PtII center. In vitro tests indicated that complex 1 displayed excellent antiproliferative activity against the tested cancer cell lines, especially liver cancer HepG-2 and SMMC-7221 cells. Importantly, the complex possessed 4.33-fold higher antiproliferative activity as compared with cisplatin against HepG-2 cells, but was less toxic to the normal cell line L02 with the selectivity index (SI = IC50(L02)/IC50(HepG-2)) value of 8.36 compared to cisplatin (SI, 1.40). The results suggested that 1 might have the potential to act as a candidate for the treatment of hepatocellular carcinoma (HCC). Cellular uptake and distribution studies showed that 1 could effectively pass through the membrane of cells, enter the nuclei and mitochondria, induce the platination of cellular DNA. The interaction of 1 with CT-DNA demonstrated that 1 could effectively bind to DNA in a dual binding mode, i.e., the intercalation of the 2-(4-aminophenyl)benzothiazole unit plus monofunctional platination of the platinum(II) moiety. In addition, Hoechst 33342 staining and flow cytometry analysis illustrated that 1 arrested the cell cycle in HepG-2 cancer cells at G2/M phases, induced mitochondrial membrane depolarization, increased ROS generation, and caused obvious cell apoptosis. Further cellular mechanism studies elucidated that 1 triggered HepG-2 cell apoptosis via the mitochondrial-mediated pathway by upregulating the gene and protein expression levels of Bax, downregulating the gene and protein expression levels of Bcl-2, and activating the caspase cascade.

The Role of Inverted Ligand Field in the Electronic Structure and Reactivity of Octahedral Formal Platinum (IV) Complexes.

Platinum complexes are ubiquitous in chemistry and largely used as catalysts or as precursors in drug chemistry, thus a deep knowledge of their electronic properties may help in planning new synthetic strategies or exploring new potential applications. Herein, the electronic structure of many octahedral platinum complexes is drastically revised especially when they feature electronegative elements such as halogens and chalcogens. The investigation revealed that in most cases the five d platinum orbitals are invariably full, thus the empty antibonding orbitals, usually localized on the metal, are mainly centered on the ligands, suggesting a questionable assignment of formal oxidation state IV. The analysis supports the occurrence of the inverted ligand field theory in all cases with the only exceptions of the Pt-F and Pt-O bonding. The trends for the molecular complexes are mirrored also by the density of states plots of extended structures featuring octahedral platinum moieties in association with chalcogens atoms. Finally, the oxidative addition of a Se-Cl linkage to a square platinum complex to achieve an octahedral moiety has been revised in the framework of the inverted ligand field.

Pt(ii) and Pt(iv) complexes with a major component of royal jelly as innovative antitumor drug candidates

The major and unique fatty acid in Royal Jelly, trans-10-hydroxy-2-decenoic acid, which have anti-tumor, immunomodulatory, and other properties, has been combined with the antitumor platinum moiety of clinically used oxaliplatin.

Design, Synthesis, and Cytotoxicity Assessment of [64Cu]Cu-NOTA-Terpyridine Platinum Conjugate: A Novel Chemoradiotherapeutic Agent with Flexible Linker.

Maximum benefits of chemoradiation therapy with platinum-based compounds are expected if the radiation and the drug are localized simultaneously in cancer cells. To optimize this concomitant effect, we developed the novel chemoradiotherapeutic agent [64Cu]Cu-NOTA-C3-TP by conjugating, via a short flexible alkyl chain spacer (C3), a terpyridine platinum (TP) moiety to a NOTA chelator complexed with copper-64 (64Cu). The decay of 64Cu produces numerous low-energy electrons, enabling the 64Cu-conjugate to deliver radiation energy close to TP, which intercalates into G-quadruplex DNA. Accordingly, the in vitro internalization kinetic and the cytotoxic activity of [64Cu]Cu-NOTA-C3-TP and its derivatives were investigated with colorectal cancer (HCT116) and normal human fibroblast (GM05757) cells. Radiolabeling by 64Cu results in a >55,000-fold increase of cytotoxic potential relative to [NatCu]Cu-NOTA-C3-TP at 72 h post administration, indicating a large additive effect between 64Cu and the TP drug. The internalization and nucleus accumulation of [64Cu]Cu-NOTA-C3-TP in the HCT116 cells were, respectively, 3.1 and 6.0 times higher than that for GM05757 normal human fibroblasts, which is supportive of the higher efficiency of the [64Cu]Cu-NOTA-C3-TP for HCT116 cancer cells. This work presents the first proof-of-concept study showing the potential use of the [64Cu]Cu-NOTA-C3-TP conjugate as a targeted chemoradiotherapeutic agent to treat colorectal cancer.

Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?

"Multi-action" Pt(IV) derivatives of cisplatin with combretastatin A4 (CA4) bioactive ligands that are conjugated to Pt(IV) by carbonate are unique because the ligand (IC50 < 10 nM) is dramatically 1000-folds more cytotoxic than cisplatin in vitro. The Pt(IV)-CA4 prodrugs were as cytotoxic as CA4 itself, indicating that the platinum moiety probably plays an insignificant role in triggering cytotoxicity, suggesting that the Pt(IV)-CA4 complexes act as prodrugs for CA4 rather than as true multi-action prodrugs. In vivo tests (Lewis lung carcinoma) show that ctc-[Pt(NH3)2(PhB)(CA4)Cl2] inhibited tumor growth by 93% compared to CA4 (67%), cisplatin (84%), and 1:1:1 cisplatin/CA4/PhB (85%) while displaying <5% body weight loss compared to cisplatin (20%) or CA4 (10%). In this case, and perhaps with other extremely potent bioactive ligands, platinum(IV) acts merely as a self-immolative carrier triggered by reduction in the cancer cell with only a minor contribution to cytotoxicity.

Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells.

Herein, we describe the synthesis, characterization, and biological properties of Pt(IV) derivatives of cisplatin with estramustine at the first axial position, which is known to disrupt the microtubule assembly and act as an androgen antagonist, and varying the second axial position using an innocent ligand (acetate or hydroxyl) to prepare dual-action and triple-action prodrugs with known inhibitors of histone deacetylase, cyclooxygenase, and pyruvate dehydrogenase kinase. We demonstrate superior antiproliferative activity at submicromolar concentrations of the prodrugs against a panel of cancer cell lines, particularly against prostate cancer cell lines. The results obtained in this study exemplify the complex mode of action of "multiaction" Pt(IV) prodrugs. Interestingly, changing the second axial ligand in the Pt-estramustine complex has a significant effect on the mode of action, suggesting that all three components of the Pt(IV) prodrugs (platinum moiety and axial ligands) contribute to the killing of cells and not just one dominant component.

Biological properties of a benzothiazole-based mononuclear platinum(II) complex as a potential anticancer agent

A mononuclear platinum(II) complex, [PtLCl]Cl (1, where L = N-(4-(benzo[d]thiazol-2-yl)phenyl)-2-(bis(pyridine-2-ylmethyl)-amino)acetamide), was synthesized by covalently tethering a benzothiazole derivative 2-(4-aminophenyl)benzothiazole to the 2,2′-dipicolylamine (DPA) chelating PtII center by an amidic bond. 1 showed a cytotoxicity comparable to that of cisplatin against MCF-7 cell lines and more potent activities against HeLa and A-549 cell lines. Investigation of the reaction of 1 with 5′-GMP displayed 1 could coordinate with N7-GMP to form the Pt-GMP adduct. Thus 1 has potential to form Pt-DNA adducts in vivo. Similarly, the glutathione (GSH) ligand could also coordinate to the PtII center to form a monodentate Pt-GS complex. The competition experiments of 1 with 5′-GMP and GSH showed that the coordination binding of 1 with GSH did not prevent formation of a certain amount of the Pt-GMP adduct in the reaction process. DNA binding experiments displayed that 1 could bind to DNA through multiple binding modes involving non-covalent interaction and monofunctional platination of the platinum(II) moiety, and induce a visible conformational change of DNA. The evaluation of the protein binding ability showed that 1 could bind to human serum albumin (HSA) with a moderate binding affinity, quench the intrinsic fluorescence of HSA, and destroy the tertiary structure of HSA.

Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism

Naphthalimide has emerged as an interesting DNA intercalator and possessed attracting antitumor properties. In this context, naphthalimide group was linked to platinum(IV) core to construct a series of new mono naphthalimide platinum(IV) derivatives. The title compounds exert effective antitumor activities to the tested tumor cells lines in vitro, especially the one with propionyl chain displays comparable or even better bioactivities than platinum(II) reference drugs cisplatin and oxaliplatin. Moreover, the mono naphthalimide platinum(IV) derivative displays comparable tumor growth inhibitory competence against CT26 xenograft tumors in BALB/c mice in vivo without severe toxic effects in contrast to oxaliplatin. A dual DNA damage mechanism was proven for the title complex. Both naphthalimide ligand and the liberated platinum(II) moiety could generate DNA lesions to tumor cells synergistically and active the apoptotic pathway by up-regulating the expression of caspase 9 and caspase 3. Meanwhile, the conversion of platinum(II) drug into tetravalent form by incorporating naphthalimide moiety increases the uptake of platinum in whole cells and DNA remarkably. All these facts might be the factors for the title platinum(IV) complexes to overcome platinum(II) drug resistance. Additionally, the mono naphthalimide platinum(IV) complex could interact with human serum albumin by hydrogen bond and van der Waals force which would further influence their storage, transport and bioactivities.

Photophysical Exploration of Dual-Approach PtII-BODIPY Conjugates: Theoretical Insights.

Two-component PtII-BODIPY dyes were recently proposed as potential multitarget agents able to conjugate the photobased photodynamic therapy (PDT) treatment with the classical chemotherapy approach based on PtII complexes. A careful first-principle investigation is herein presented on the above-mentioned conjugates (Pt-1 and Pt-2) and on the two metal-free precursors (1 and 2), aimed at revealing the influence of the platinum moiety on the physicochemical behavior of the photosensitizer (PS) and to inspect, in turn, the possible modulation of the hydrolysis rate of the PtII ligand induced by the PS. The investigated photophysical properties for singlet and triplet states and the amplitude of the computed spin-orbit matrix elements reveal that the Pt-containing systems are able to enhance the cytotoxic 1O2 production. The PtII moiety, instead, follows an activation mechanism similar to that previously found for cisplatin and its analogues already used in cancer therapy.

Evolution of Pt and Pd species in functionalized UiO-67 metal-organic frameworks

Abstract Functionalization of metal-organic frameworks (MOFs) with noble metals is a promising way for producing new versatile catalysts that will combine the outstanding porosity and specific surface area of MOFs with high catalytic activity of metals. Here, we present a comparative study of two metal-organic frameworks with UiO-67 topology, functionalized with palladium and platinum moieties. The initial structure of all studied samples contained palladium or platinum atoms grafted into MCl2bpydc (M = Pd, Pt) linkers of MOFs. The materials were further activated by heating in inert and H2-containing atmospheres. Both Pd- and Pt- functionalized materials exhibited high thermal stability upon heating in these atmospheres. The evolution of Pt and Pd species during the activation procedure was monitored by in situ time-resolved X-ray absorption near-edge structure (XANES) spectroscopy. We applied multivariate curve resolution alternating least squares (MCR-ALS) approach to XANES to unravel the intermediates which can be formed during the activation procedure. For UiO-67-Pd, only simple one-step transformation from PdCl2bpydc to Pd nanoparticles (NPs) was observed. For UiO-67-Pt, two additional intermediate states were observed, which behave differently depending on the activation procedure. Theoretical calculation of XANES spectra allowed us to suggest the 3D-atomic structures corresponding to each of the pure spectra determined by MCR-ALS. In addition, reaction enthalpies for different possible reaction routes were calculated within a density functional theory approach. Based on the experimental and theoretical results showed that Pd nanoparticles (NPs) tend to be formed in UiO-67-Pd samples irrespective of the activation procedure, while either Pt NPs or isolated PtII active sites, grafted in the MOF framework may be formed in UiO-67-Pt samples depending on the activation temperature and atmosphere.

An Anticancer PtIV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects.

Dual- or multi-action PtIV prodrugs represent a new generation of platinum anticancer drugs. The important property of these PtIV prodrugs is that their antitumor action combines several different mechanisms owing to the presence of biologically active axial ligands. This work describes the synthesis and some biological properties of a "triple-action" prodrug that releases in cancer cells cisplatin and two different epigenetically acting moieties, octanoate and phenylbutyrate. It is demonstrated, with the aid of modern methods of molecular and cellular biology and pharmacology, that the presence of three different functionalities in a single molecule of the PtIV prodrug results in a selective and high potency in tumor cells including those resistant to cisplatin [the IC50 values in the screened malignant cell lines ranged from as low as 9 nm (HCT-116) to 74 nm (MDA-MB-231)]. It is also demonstrated that cellular activation of the PtIV prodrug results in covalent modification of DNA through the release of the platinum moiety accompanied by inhibition of the activity of histone deacetylases caused by phenylbutyrate and by global hypermethylation of DNA by octanoate. Thus, the PtIV prodrug introduced in this study acts as a true "multi-action" prodrug, which is over two orders of magnitude more active than clinically used cisplatin, in both 2D monolayer culture and 3D spheroid cancer cells.

Synthesis, Characterization, and Stability of α‐Keggin‐Type Polyoxotungstate‐Coordinated Mono‐Platinum(II) Complex

The first example of mono‐platinum(II) complex composed of mono‐lacunary α‐Keggin‐type polyoxotungstate is described. The mono‐platinum(II)‐containing polyoxotungstate [(CH3)4N]4H[α‐PW11O39{cis‐PtII(Me2ppz)}]·5H2O (Me2ppz = N,N′‐dimethylpiperazine) (TMA‐1) was synthesized by a 1:1 stoichiometric reaction of mono‐lacunary α‐Keggin polyoxotungstate, [α‐PW11O39]7–, with cis‐PtCl2(Me2ppz) in an aqueous solution, followed by purification from water. The compound TMA‐1 was characterized by elemental analysis, thermogravimetric/differential thermal analysis (TG/DTA), and Fourier transform infrared (FTIR), ultraviolet‐visible (UV/Vis), and solution {1H, 13C, 31P, 195Pt, and 183W} nuclear magnetic resonance (NMR) spectroscopy. The characterization results indicated that a platinum(II) moiety, [cis‐Pt(Me2ppz)]2+, was coordinated to two oxygen atoms in a mono‐vacant site of [PW11O39]7– with asymmetric configuration, resulting in an overall C1 symmetry. The polyoxoanion [α‐PW11O39{cis‐PtII(Me2ppz)}]5– (1) was more stable in dimethylsulfoxide and water than the α‐Keggin‐type polyoxotungstate‐coordinated mono‐platinum(II) complex, [α‐PW11O39{cis‐Pt(NH3)2}]5–, which was also obtained by the reaction of [α‐PW11O39]7– with cis‐diamminedichloroplatinum(II) in an aqueous solution.

Photochromic DTE-Substituted-1,3-di(2-pyridyl)benzene Platinum(II) Complexes: Photomodulation of Luminescence and Second-Order Nonlinear Optical Properties.

We disclose a new family of photochromic cyclometalated platinum(II) complexes (PtDTE1 and PtDTE2), where a dithienylethene (DTE) unit is connected at the para-position of the central phenyl ring of (N^C^N) cyclometalated ligand, through two different linkages. Their syntheses are presented along with the X-ray characterizations of both the open and closed isomers of PtDTE1. The investigation of their photophysical properties is made, including absorption, photochromism, emission, and second-order nonlinear properties. We report a quantitative photoisomerization for both PtDTE1 and PtDTE2, irrespective of the nature of the connecting mode between the DTE unit and the platinum(II) moiety. The efficient photochromism allows a significant NLO photomodulation, both in solution and in thin films. In addition, we show that the photoluminescence of the PtDTE1 and PtDTE2 can be controlled by the open/closed isomerization of the DTE unit.

Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action

A novel compound, Cou-platin, composed of 7-hydroxycoumarin and a platinum(IV) moiety derived from cisplatin was designed and synthesized. Significantly, Cou-platin exhibited more potent in vitro antitumor activity against all tested cancer cell lines than that of cisplatin, which was mainly attributed to the liberation of cisplatin and 7-hydroxycoumarin upon reduction with a biomolecular agent. Besides, cellular accumulation of Cou-platin was dramatically increased among several cancer cells in contrast to cisplatin. Flow cytometry study revealed that Cou-platin arrested cell cycle at G2 phase and induced cell apoptosis. Western blots results indicated that it not only activated cell apoptosis pathway, but also inhibited extracellular regulated protein kinases/mitogen-activated protein kinase pathway. In vivo tests showed that Cou-platin, at equimolar dose to cisplatin, could inhibit tumor growth in nude mouse HCT116 tumor xenograft models almost as cisplatin and oxaliplatin, but with less toxicity.

Covalent and non-covalent binding of platinated vitamin B12-derivatives to a B12 responsive riboswitch

The B12 responding btuB riboswitch is a short, non-coding RNA sequence involved in the gene-regulation of an outer membrane B12-transport protein in E. coli. This RNA is characterized by its selective high-affinity binding to coenzyme B12 and by the structural rearrangement it undergoes upon this interaction. Due to their involvement in (mostly) bacterial gene regulation, the btuB riboswitch as well as the further about twenty known classes of riboswitches received much attention in recent years. In case of the btuB riboswitch, the light sensitivity of its ligand, coenzyme B12, poses one of the greater challenges for its investigation. Vitamin B12 derivatives carrying a cyanide-bridged platinum(II) moiety offer an ideal strategy for the design of light stable coenzyme B12 analogs. Developed by Alberto and coworkers in 2005 these conjugates provide the possibility to coordinate an additional nucleobase making them potential coenzyme B12 mimics. However, although these derivatives show a high structural similarity to coenzyme B12, their functionality might differ and offers the opportunity to develop new classes of antibiotic agents. Especially the platinum(II)-complex could interact with RNA in an unexpected way, which is the main question addressed in the work presented here. We characterized the binding of three vitamin B12-platinum(II) complexes to two different RNAs: the B12-specific btuB riboswitch and the short RNA D1-45, which is a non-B12-binder. cisPt(II)VitB12+ (1) and enPt(II)VitB12+ (2) carry both a labile chloride ligand at the platinum(II) moiety whereas dienPt(II)VitB122+ (3), that carries no labile chloride ligand anymore, can be considered chemically inert under the applied conditions. Complexes 1 and 2 covalently bind to both RNAs as monitored by band-shift assays. In the case of the short D1-45 the shifted bands are well separated and were further analyzed by MALDI-MS proving the covalent interaction. Complex 3 is unable to covalently bind any of the two RNAs, which proves the general stability of the Pt(II) complex. However, the presence of this moiety has a dramatic influence on the binding property towards the B12-sensing riboswitch, as was observed in in-line probing assays by comparison to the natural ligand coenzyme B12.

Undervalued N3 Coordination Revealed in the Cisplatin Complex with 2'-Deoxyadenosine-5'-monophosphate by a Combined IRMPD and Theoretical Study.

The complex obtained by the reaction of cisplatin and 2'-deoxyadenosine-5'-monophosphate (5'-dAMP) in water has been isolated and detected by electrospray ionization mass spectrometry. The so-formed cis-[PtCl(NH3)2(5'-dAMP)]+ complex has been studied in detail by infrared multiple photon dissociation (IRMPD) spectroscopy in two spectral ranges, namely, 700-1900 and 2800-3800 cm-1, backed by quantum-chemical calculations at the B3LYP/LACV3P/6-311G** level of theory. In agreement with the computational results, the vibrational spectroscopic characterization of cis-[PtCl(NH3)2(5'-dAMP)]+ shows that the sampled ionic population comprises two major isomers, differentiated in the X-H stretching region by their distinct fragmentation patterns. One of these species presents coordination of the platinum moiety at the N3 position of adenine, whereas in the second one, platinum is bound at the N1 position of adenine. IRMPD kinetics have allowed an estimation of their relative proportions. Surprisingly, the most abundant component of cis-[PtCl(NH3)2(5'-dAMP)]+ is the N3 isomer, although it is slightly less stable than the other potential isomers in the gas phase. In contrast, the lowest-energy species, namely, the one showing cisplatin binding to the N7 position of adenine, seems to be the one less represented in the sampled ionic population. These findings suggest that the reaction of cisplatin with 5'-dAMP is governed by the kinetics of the process occurring in solution rather than by the thermodynamic factors.